The last twelve to eighteen months have not been easy on NuVasive (NUVA).
Once a darling of growth-oriented investors in the med-tech space,
NuVasive got knocked off stride by a combination of sluggish growth in
its core spine market, increasing competition, an IP litigation loss to Medtronic (MDT),
a questionable acquisition, and just a generalized ennui on the part of
investors frustrated with the pace of progress at this small-cap
orthopedics company.
To read more, please continue here:
NuVasive Could Do Better, But Will It?
No comments:
Post a Comment